DBV Technologies S.A.(DBVT)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings.

DBV Technologies S.A. (DBVT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DBVT at 4.6/100 on a 32-signal composite quality model, placing it at rank #2,955 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), DBV Technologies S.A. reports quarterly revenue of $700.0K, net income of $-50.4M, free cash flow of $-53.0M. Top institutional holders of DBVT by reported 13-F value include MPM BioImpact, Siren, L.L.C., Vivo Capital, based on the most recent SEC filings. DBVT trades on the Nasdaq exchange and files with the SEC under CIK 1613780. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DBVT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for DBV Technologies S.A. directly from SEC EDGAR.